Renal Function, Peak Anti‐Xa Levels and Enoxaparin Dosing

Publisher： John Wiley & Sons Inc

E-ISSN： 2055-2335|34|1|14-17

ISSN： 1445-937x

Source： JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol.34, Iss.1, 2004-03, pp. : 14-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Elderly Medical Patients Treated with Prophylactic Dosages of Enoxaparin: Influence of Renal Function on Anti-Xa Activity Level

By Mahe Isabelle  

Drugs & Aging, Vol. 24, Iss. 1, 2007-01 ,pp. : 63-71

Adis International

Access to resources Recommend Favorite

Comparison of Anti-Xa Activity After a Single Intravenous Bolus of Low-dose Enoxaparin in Patients With and Without End-stage Renal Disease

By Lin J-S   Wang W-J   Lin W-C   Wu X-M   Chao C-L  

The Journal of International Medical Research, Vol. 37, Iss. 6, 2009-11 ,pp. : 1890-1896

Field House Publishing

Access to resources Recommend Favorite

Routine Plasma Anti-Xa Monitoring is Required for Low-Molecular-Weight Heparins

By Al-Sallami Hesham S.  

Clinical Pharmacokinetics, Vol. 49, Iss. 9, 2010-09 ,pp. : 567-571

Adis International

Access to resources Recommend Favorite

Renal function-based contrast dosing reduces nephropathy risk

By  

Reactions Weekly, Vol. 1, Iss. 1368, 2011-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Plasma Anti-Xa Monitoring for Low-Molecular-Weight Heparins in Patients with Chronic Kidney Disease

By Gallieni Maurizio  

Clinical Pharmacokinetics, Vol. 49, Iss. 11, 2010-11 ,pp. : 773-774

Adis International

Access to resources Recommend Favorite